Mercer Global Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Mercer Global Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Buy	1,336 +271	+25%	+$63.3K	﹤0.01%	2625
2026 Q1	$244K	Buy	1,065 +7	+0.7%	+$1.57K	﹤0.01%	2648
2025 Q4	$226K	Hold	1,058	–	–	﹤0.01%	2465
2025 Q3	$210K	Sell	1,058 -2,070	-66%	-$386K	﹤0.01%	2359
2025 Q2	$540K	Buy	+3,128	New	+$510K	﹤0.01%	1532

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mercer Global Advisors's ASND Position: Q2 2026 in Review

Mercer Global Advisors increased its Ascendis Pharma A/S (ASND) stake by 25% in Q2 2026, buying an estimated $63.3K and bringing the position to 1,336 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

Mercer Global Advisors first reported a position in ASND in Q2 2025 and has held it in 5 quarters since. The position peaked at $540K in Q2 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Mercer Global Advisors held 1,336 shares of Ascendis Pharma A/S worth $356K as of Q2 2026.
Mercer Global Advisors bought 271 Ascendis Pharma A/S shares in Q2 2026, an estimated $63.3K.
Ascendis Pharma A/S made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2625 holding.
Mercer Global Advisors first reported a position in Ascendis Pharma A/S in Q2 2025 and has held it in 5 quarters since.
Mercer Global Advisors's Ascendis Pharma A/S position peaked at $540K in Q2 2025.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.